We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

血检能预测肺癌的最佳治疗

By LabMedica International staff writers
Posted on 04 Jan 2017
Print article
图片:两个肺癌细胞的扫描电镜彩色显微图像(SEM)(图片蒙英国癌症研究所的Anne Weston惠赐)。
图片:两个肺癌细胞的扫描电镜彩色显微图像(SEM)(图片蒙英国癌症研究所的Anne Weston惠赐)。
一项血检能预测小细胞肺癌(SCLC)患者的治疗效果有多好。小细胞肺癌是一种能转移的侵犯性疾病,大多数患者起初对化疗敏感,然后对化疗产生耐受从而导致疾病复发。

然而,少数小细胞肺癌患者初次治疗后的三个月内就复发;这种情况定义为化疗不应。区分化疗敏感与化疗不应的分子机制目前尚不得而知。

英国曼彻斯特大学曼彻斯特癌症研究所的科学家检查了经过预处理的SCLC血样中循环肿瘤细胞(CTC)的拷贝数异常(CNA),以确定区分化疗敏感与化疗不应的基因特征。分析了从13名患者身上分离的88个CTC(训练集)后,他们生成了基于CNA的分类器,用另外18名患者(测试集,112份CTC样本)和SCLC患者身上得到的6例CTC外植肿瘤进行确证。

分类器将83.3%的病例正确归类为化学不应或化学敏感。进而观察到基线CNA分类器所判定的化疗不应患者与化疗敏感患者的无进展生存率(PFS)明显不同。值得注意的是,一开始对化疗敏感的5名患者后来复发时得到的CTC CNA特征值没变成化疗不应的CNA特征值,说明其初始化疗耐受的基因基础有别于本身获得的化疗耐受。

该研究的论文发表于2016年11月21日的《自然》杂志《医学》分册。领衔作者Caroline Dive博士说:“我们的研究显示如何用血样预测肺癌患者的治疗效果。遗憾的是,小细胞肺癌患者可选的治疗方案很少,而对化疗产生耐受的患者则更是无从选择。我们既然发现了不同患者基因缺陷模式的差异,就可以从这里开始着手理解这一侵染性肺癌的患者是如何产生耐药性的。”

Related Links:
英国曼彻斯特癌症研究所

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more